About ZYTIGA® (abiraterone acetate)

What is ZYTIGA®

ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Since its approval in 2011, more than 100,000 men in the U.S. have been prescribed ZYTIGA®.1

Estimate based on sales and use data from April 2011 to December 2016.

About Zytiga

Efficacy of Zytiga

Efficacy of ZYTIGA®

Significant results and an established safety profile.

Accessing ZVT

Accessing ZYTIGA®

Identifying the cost support options available to your patients.

Prednisone

ZYTIGA® + Prednisone

Understanding the role of prednisone in treatment.

Janssen

The Janssen Commitment

General Tags: 

How ZYTIGA® Works

Mechanism of Action

Abiraterone acetate (ZYTIGA®) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17α-hydroxylase/C17, 20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.

There are multiple sources of androgen, including the testes and adrenal glands. However, in metastatic castration-resistant prostate cancer, the tumor itself can be an additional source of androgen production.

Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess—Use with caution in patients with a history of cardiovascular disease or with medical conditions that might be compromised by increases in blood pressure, hypokalemia, or fluid retention. ZYTIGA® may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Safety has not been established in patients with LVEF <50% or New York Heart Association (NYHA) Class III or IV heart failure (in Study 1) or NYHA Class II to IV heart failure (in Study 2) because these patients were excluded from these randomized clinical trials. Control hypertension and correct hypokalemia before and during treatment. Monitor blood pressure, serum potassium, and symptoms of fluid retention at least monthly.

Go to Efficacy & Safety >>

References: 1. Data on file. Janssen Biotech, Inc

General Tags: